Instem (INS)

 

INS Share PerformanceMore

52 week high328.55 26/09/16
52 week low195.25 05/02/16
52 week change 11.50 (5.54%)
4 week volume222,543 07/11/16

Media for (INS)

Presenter: Phil Reason, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Trading Statement

RNS Number: 6540P Instem plc 21 November 2016 21 November 2016 Instem plc ("Instem", the "Company" or the "Group") Trading Statement The Group's interim results announcement in September referred to a slow-down in the early phase clinical market that is served by Instem Clinical, which had impacted Instem Clinical's trading performance. At the time of...

Holding(s) in Company

RNS Number: 5032K Instem plc 22 September 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Instem plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or dispos...

Issue of Equity

RNS Number: 4166K Instem plc 21 September 2016 Instem plc ("Instem", the "Company" or the "Group") Issue of Equity and Total Voting Rights Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of share options by employees, 60,446 ordinary shares of 10p each in the Co...

Instem worth 24% more

Instem remains bullish following a great first half and the City thinks its high-flying share price has further upside, repor...

Instem revenues up 21%

Instem's revenues increased 21% to 9.1m in the six months to the end of June with recurring revenues up 6% at 5.3m. EBITD...

Half-year Report

RNS Number: 1341K Instem plc 19 September 2016 Instem plc ("Instem", the "Company" or the "Group") Half Yearly Report Instem plc (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces its unaudited half year results for the six months ended 30 June 2016. Financial Highlights Revenues increased 21% to 9.1m...

Instem acquires Notocord

Instem, a leading provider of IT solutions to the global early development healthcare market, has acquired Notocord. The t...

Earnings Enhancing Acquisition of Notocord?

RNS Number: 9946I Instem plc 05 September 2016 Instem plc ("Instem") Earnings Enhancing Acquisition of Notocord Systems SAS ("Notocord") Acquisition of software provider in pre-clinical studies Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces that it has acquired Notocord (the "Acquisition")...

Fundamental DataMore

EPS-3.5
Dividend yield0 %

Equity Research (INS)

progressive research
Instem plc
19/09/2016
Instem has announced solid interim results. Revenues grew by 21% YoY, accompanied by a 34% improvement in EBITDA. Activity in the pre-clinical segment remains strong, as evidenced by the multi-year...
progressive research
Instem plc
08/09/2016
Instem, a leading provider of software and services to the earlystage drug development healthcare market, has announced the acquisition of France-based Notocord, a profitable software business active...
progressive research
Instem plc
02/06/2016
Instem has acquired a small software business, Samarind, which is active in the market for Regulatory Information Management – helping pharmaceutical companies deliver required details about products...

Latest discussion posts More

  • NEW ARTICLE: Instem worth 24% more

    "I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth A#22 million and demand for its software, which helps drug companies develop commercial drugs ...
    19-Sep-2016
    II Editor

Users' HoldingsMore

Users who hold Instem also hold..
IQE33%
BT GROUP26%
ANPARIO26%
VECTURA26%
GLAXOSMITHKLINE26%

Codes & Symbols

ISINGB00B3TQCK30
SymbolsINS, LSE:INS, INS.L, INS:LN, LON:INS, XLON:INS